Generate Biomedicines (NASDAQ:GENB) Rating Increased to Hold at Wall Street Zen

Key Points

• Wall Street Zen upgraded Generate Biomedicines from “Sell” to “Hold.” Other analysts remain more bullish, with six Buy ratings, one Hold, and one Sell, producing a consensus “Moderate Buy” rating and an average price target of $26.40.
• GENB shares closed at $15.33, giving the company a market capitalization of approximately $1.97 billion; the stock has traded between $11.00 and $22.67 over the past year.
• Generate Biomedicines reported a quarterly loss of $0.52 per share, missing the $0.48 consensus estimate, while revenue totaled $6.31 million. Analysts expect a full-year loss of approximately $2.29 per share.

Generate Biomedicines (NASDAQ:GENB - Get Free Report) was upgraded by Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Saturday.

GENB has been the topic of several other reports. Weiss Ratings started coverage on shares of Generate Biomedicines in a report on Tuesday, August 11th. They set a "sell (d)" rating on the stock. HC Wainwright boosted their price target on Generate Biomedicines from $25.00 to $30.00 and gave the company a "buy" rating in a research note on Friday. Finally, Morgan Stanley raised their price objective on Generate Biomedicines from $20.00 to $22.00 and gave the stock an "overweight" rating in a research note on Thursday, May 14th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $26.40.

Generate Biomedicines Price Performance

GENB stock traded down $0.44 during trading hours on Friday, hitting $15.33. 2,353,064 shares of the stock were exchanged, compared to its average volume of 1,181,209. The firm has a 50-day moving average price of $15.27. The firm has a market cap of $1.97 billion and a price-to-earnings ratio of -9.64. Generate Biomedicines has a 12 month low of $11.00 and a 12 month high of $22.67.

Generate Biomedicines (NASDAQ:GENB - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.04). The company had revenue of $6.31 million for the quarter. Equities research analysts anticipate that Generate Biomedicines will post -2.29 EPS for the current year.

Hedge Funds Weigh In On Generate Biomedicines

Several hedge funds have recently bought and sold shares of GENB. California State Teachers Retirement System acquired a new position in shares of Generate Biomedicines in the 2nd quarter valued at approximately $96,000. Susquehanna International Group LLP acquired a new stake in shares of Generate Biomedicines during the 2nd quarter worth approximately $196,000. AXQ Capital LP bought a new position in Generate Biomedicines in the second quarter valued at approximately $218,000. Bank of New York Mellon Corp bought a new position in Generate Biomedicines in the second quarter valued at approximately $967,000. Finally, Braidwell LP acquired a new position in Generate Biomedicines during the second quarter valued at approximately $55,398,000.

Generate Biomedicines Company Profile

Generate Biomedicines, Inc NASDAQ: GENB is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source